• Defining Retroviruses
• 38 min
  1. An introduction to retroviruses: replication strategy and genetics

  • Dr. Jonathan Stoye
• The First Human Retroviruses
• 65 min
  2. The discovery of human retroviruses and how they cause disease

  • Prof. Robert Gallo
• HIV Transmission, Epidemiology and Public Health/Prevention Issues
• 42 min
  3. HIV/AIDS epidemiology, transmission, and risk factors

  • Prof. William Blattner
• 55 min
  4. HIV prevention and public health issues: a global perspective

  • Prof. Sten H. Vermund
• How HIV causes AIDS
• 35 min
  5. How HIV causes disease 1: identification and characterization of HIV

  • Prof. Bruce Walker
• 43 min
  6. How HIV causes disease 2: immune responses to HIV infection

  • Prof. Bruce Walker
• HIV Therapy - Now and the Future
• 34 min
  7. HIV therapy: taking advantage of progress

  • Prof. Paul Volberding
• 39 min
  8. HIV cure: harnessing innate and adaptive strategies

  • Prof. Luis Montaner
• Archived Lectures *These may not cover the latest advances in the field
• 36 min
  9. The first human retroviruses: the human T lymphotropic viruses (HTLVs)

  • Prof. William Hall
• 59 min
  10. HIV preventive vaccines

  • Prof. Andrew McMichael
• 31 min
  11. HIV/AIDS in the developing world: what can we do?

  • Dr. Joseph O'Neill
• 54 min
  12. Human T-cell leukemia virus type 1 (HTLV-1) and adult T-cell leukemia: insights into cellular transformation

  • Prof. Kuan-Teh Jeang
• 41 min
  13. Antiretroviral therapy 2007, new concepts and lessons learned

  • Prof. Robert Redfield
• 29 min
  14. What to do in therapy in the face of HIV drug resistance?

  • Prof. Mark Wainberg
• 42 min
  15. Viral reservoirs, latency and mechanisms of HIV persistence

  • Prof. Robert Siliciano
• 28 min
  16. HIV preintegration complexes

  • Prof. Lee Ratner
• 30 min
  17. The discovery of ATL field expansion in 40 yrs

  • Prof. Junji Yodoi
• 45 min
  18. Bovine leukemia virus

  • Prof. Arsene Burny
  • Dr. Lucas Willems
• 11 min
  19. HIV: peculiarities of its genome

  • Dr. George Pavlakis

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Transmission of MDR in primary HIV-1 infection
3. IQ and the genetic barrier
4. E-184V study
5. E-184V study design
6. Results: 3TC alone vs. treatment interruption
7. Lamivudine activity as MDR HIV-1 infection therapy
8. Characteristics of study subjects at entry
9. Presence of 184V mutation in the absence of 3TC
10. Level of viral load in the absence of 3TC
11. Partial treatment interruptions (change in viral load)
12. Phenotypic sensitivity to Tipranavir
13. Phenotypic resistance of multi-PI-resistant isolates
14. TPV resist studies (1)
15. TPV resist studies (2)
16. TPV resist studies (3)
17. Efficacy of TMC125
18. Time to virological failure
19. MONARK trial
20. MONARK trial results: HIV RNA levels
21. SPREAD trial: transmitted drug resistance
22. Transmitted drug resistance over time
23. MK-0518: potent activity of integrase inhibitor
24. MK-0518 vs. EFV: HIV RNA levels
25. Potential benefits of MVC (entry inhibitor)
26. Phase II trial of efficacy and safety of vicriviroc
27. Summary

Topics Covered

• Drug resistance in HIV disease can occur for each drug used in therapy
• Drug resistant forms of HIV can be sexually transmitted
• Drug resistance can be selected by antiviral drugs
• HIV mutations can interact with one another to affect phenotype
• Newer drugs in each class can work against resistant forms of HIV
• New drug classes continue to be developed

Links

Series:

• Retroviruses

Categories:

• Clinical Practice
• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Infectious Diseases

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on October 28, 2018

Financial Disclosures

• Prof. Mark Wainberg has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.